ESMO WCGIC 2023 | Should HCC be treated with locoregional or systemic therapies?

Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the role of locoregional versus systemic treatment in patients with hepatocellular carcinoma (HCC). Whilst sorafenib has proven not to be efficacious in previous studies, immune checkpoint inhibitors have shown encouraging signals. The Phase III EMERALD-3 trial (NCT05301842) of tremelimumab and durvalumab with or without lenvatinib has demonstrated the viability of immunotherapy in this setting. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.